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HLA-DR is a host-derived protein present at the surface of HIV-1. To clarify the mechanism through which this molecule is inserted
within viruses, we monitored whether the incorporation process might be influenced by the level of virus-encoded envelope (Env)
glycoproteins. Wild-type virions and viruses either lacking or bearing lower levels of Env were produced in different cell types. Results from
a virus capture test indicate that HLA-DR is efficiently incorporated and at comparable levels in the tested virus preparations. Therefore, Env
does not play an active role in the acquisition of host HLA-DR by emerging HIV-1 particles.
D 2005 Elsevier Inc. All rights reserved.
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env genes encode for polyproteins Pr55Gag and gp160,
respectively. The latter is the precursor of the gp120 and
gp41 glycoproteins that are forming the mature virus
envelope (Env), which facilitates binding of the virus to
target cells and mediates fusion and entry. During viral
assembly, the matrix (MA) domain of Pr55Gag interacts with
Env, a process leading to the packaging of Env glycopro-
teins into newly formed viral entities (Dorfman et al., 1994;
Freed and Martin, 1995; Yu et al., 1992). Thereafter, virions
egress from the producer cell and it is during this step that
HIV-1 acquires a large collection of host cell membrane
constituents. It has been reported that HIV-1 may actually
benefit from such embedded surface molecules (reviewed in
Tremblay et al., 1998). Yet, the mechanism underlying the
incorporation process of host-derived molecules is poorly
understood and efforts have to be put forward into defining
this phenomenon thoroughly since it might modulate the
pathogenesis caused by this human retrovirus. To work
towards this end, we attempted to define whether HLA-DR0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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based on a previous study suggesting that Env is mandatory
for the efficient insertion of human leukocyte antigen (HLA)
class II proteins within HIV-1 (Poon et al., 2000). Indeed,
Poon and coworkers demonstrated that the presence of Env
glycoproteins, and more particularly the gp41 cytoplasmic
tail, is necessary to achieve incorporation of HLA class II
proteins in virions produced by the human T lymphoid cell
line H9 and peripheral blood mononuclear cells (PBMCs).
HLA-DR, a product of major histocompatibility complex
(MHC) class II genes, is a heterodimer formed by non-
covalently bound a- and h-transmembrane chains pro-
longed by short cytoplasmic domains. This HLA determi-
nant is a well-studied molecule in the context of
incorporation of host molecules into HIV-1 (Cantin et al.,
1997a, 1997b; Castilletti et al., 1995; Rossio et al., 1995).The acquisition of HLA-DR by HIV-1 produced in 293T
cells is independent of Env
Progeny viruses were initially generated in 293T cells
using a well established transient transfection-and-expres-05) 286–290
Fig. 1. Incorporation of host HLA-DR in viruses produced in 293T cells.
WT, 34VE, 30LE, and Env/Nef viruses were produced in HLA-DR-
expressing 293T cells and incubated with streptavidin-coated magnetic
beads tagged with biotinylated anti-HLA-DR antibodies (2.06) or isotype-
matched irrelevant antibodies (IgG2a). The amounts of precipitated viruses
were estimated with a p24 test. Data shown are the meansF SD of triplicate
samples and are representative of three independent experiments. Compar-
ison of means using single-factor ANOVA and Dunnett’s test indicates that
there are no statistically significant differences between levels of
immunoprecipitated WT, 34VE, 30LE, or Env/Nef viruses by anti-
HLA-DR antibodies ( P b 0.05).
Rapid Communication 287sion system (Fortin et al., 1997, 1998; Paquette et al., 1998).
Briefly, 293T cells were co-transfected with a plasmid
encoding for the class II transactivator (CIITA) (Khalil et al.,
2002) to drive expression of MHC class II determinants and
plasmids coding for HIV-1 viruses bearing various levels of
gp120 (NL4-3 backbone). The molecular clones of HIV-1
that were used in this study include wild type (WT) NL4-3
(Adachi et al., 1986), two NL4-3 matrix mutants (34VE and
30LE) (Freed and Martin, 1995, 1996), a NL4-3 plasmid
deficient for both Env and Nef (Env/Nef) (Connor et al.,
1995), and a NL4-3 vector deficient for Env only (Env/
Nef+) (Ott et al., 1999). Table 1 shows the levels of virus-
associated gp120 and p24 determined by ELISA (Paquette
et al., 1998) and molar ratios of gp120 to p24 calculated on
the basis of their respective molecular masses (i.e., 120 and
24 kDa, respectively) as described previously (Beause´jour
and Tremblay, 2004a). Based on these molar ratios, WT,
34VE, 30LE, Env/Nef, and Env/Nef+ viruses dis-
played 100%, 21%, 4%, 0%, and 0% gp120, respectively.
Virus stocks were ultrafiltrated (Centricon Plus-20 Biomax-
100 filter devices, Millipore Corporation) to eliminate free
p24. Then, viruses were submitted to a virus capture assay
comprising streptavidin-coated magnetic beads (Dynal
Biotech Inc.) and biotinylated monoclonal antibodies
(anti-HLA-DR, clone 2.06), followed by determination of
p24 concentration by a homemade enzymatic test (Martin
and Tremblay, 2004). Beads coated with an isotype-matched
(i.e., IgG2a) irrelevant antibody were used as controls. As
illustrated in Fig. 1, comparable amounts of viruses were
captured by HLA-DR-tagged beads in the WT, 34VE,
30LE, and Env/Nef populations, thus suggesting that
HLA-DR incorporation is not influenced by the degree of
virus-associated Env glycoproteins. Given that Nef is
influencing the budding site of HIV-1 (Zheng et al., 2001)
which could in turn affect the incorporation process based
on the idea that HIV-1 has been shown to egress from
infected cells through specialized microdomains called lipid
rafts (Chazal and Gerlier, 2003), similar experiments were
also conducted with an Env-deficient vector that carries Nef.Table 1
gp120 associated to wild type and mutated HIV-1 virions
Virus stocks gp120
(ng/ml)a
p24
(ng/ml)a
gp120/p24
molar ratios
(102)
gp120/p24
(%)b
WT 19.0 F 0.9 161 F 8 2.4 100
34VE 31 F 1 1202 F 55 0.5 21
30LE 0.50 F 0.03 103 F 5 0.1 4
Env/Nef 0 NT NA NA
Env/Nef+ 0 NT NA NA
Results are the mean F standard deviation of triplicates and are
representative of three independent experiments. NT, not tested; NA, not
applicable.
a The amounts of virus-associated gp120 and p24 were determined by
enzymatic assays.
b The percentage of gp120 associated to virions of the wild type stock was
arbitrarily fixed to 100.Data from the virus capture assay using samples from two
separate transfection experiments confirmed that host-
encoded HLA-DR molecules are acquired by HIV-1
particles devoid of Env glycoproteins (Fig. 2). Altogether,
these results also indicate that Nef is not contributing to the
efficient insertion of HLA-DR within mature HIV-1
particles.Fig. 2. Efficient incorporation of host HLA-DR in viruses produced in 293T
cells. WT and Env/Nef+ viruses were produced in HLA-DR-expressing
293T cells and incubated with streptavidin-coated magnetic beads tagged
with biotinylated anti-HLA-DR antibodies (2.06) or isotype-matched
irrelevant antibodies (IgG2a). The amounts of precipitated viruses were
estimated with a p24 test. Data shown are the means F SD of triplicate
samples.
Fig. 3. Insertion of host HLA-DR in HIV-1 particles produced in primary
human cells. WT, 34VE, and 30LE viruses pseudotyped with VSV-G were
first produced in 293T cells and next used to infect autologous MDMs and
CD4+ T cells from three different healthy donors (A, B, and C). Progeny
viruses were incubated with streptavidin-coated magnetic beads labeled
with biotinylated anti-HLA-DR antibodies (2.06) or isotype-matched
irrelevant antibodies (IgG2a). The amounts of precipitated viruses were
estimated with a p24 test. Data shown are the means F SD of triplicate
samples.
Rapid Communication288Env glycoproteins are not responsible for HLA-DR
incorporation in virions produced in more natural
cellular reservoirs
Although studies performed in 293T cells are informative,
this human epithelial cell line might bear features distinct
from the more natural cellular reservoirs of HIV-1, i.e.,
mononuclear cells from the immune system. Moreover, we
wanted to validate our findings in the same cell types that
were used to demonstrate the importance of Env packaging
in HLA class II acquisition by HIV-1 (Poon et al., 2000).
This goal was achieved by first producing WT and Env/
Nef viruses pseudotyped with the broad-host-range vesic-
ular stomatitis virus envelope glycoprotein G (VSV-G) in
293T cells. The pseudotyping strategy with VSV-G allows
bypassing the natural mode of HIV-1 entry and not only
broadens the natural virus tropism but also significantly
enhances virus infectivity (Luo et al., 1998). Next, pseudo-
typed viruses were used to infect H9 cells and PBMCs from
three healthy donors that were stimulated for 72 h with PHA-
L (1 Ag/ml: Sigma) and recombinant human IL-2 (50 U/ml).
Additionally, RAJI-CD4 cells were also infected with
pseudotyped viruses because these cells express high levels
of MHC class II molecules (Accolla, 1983). Viruses released
from infected cells were ultrafiltrated and subjected to the
virus capture test. In agreement with our findings with 293T
cells, both WT and Env/Nef-deficient viruses produced by
PBMCs, H9, and RAJI-CD4 cells were found to acquire host
HLA-DR at comparable levels (data not shown).
Studies were also carried out in the two cellular subsets
recognized as the major reservoirs of HIV-1, namely
macrophages and CD4+ T lymphocytes. Autologous mono-
cyte-derived macrophages (MDMs) and purified CD4+ T
cells were obtained from three healthy donors before
infection with VSV-G pseudotyped WT, 34VE, and 30LE
viruses. Once again, we could not draw any conclusion on
the possible involvement of Env glycoproteins in the
efficient incorporation of host-derived HLA-DR into the
virion. Indeed, as shown in Fig. 3, viruses that carry very
low amounts of gp120 (i.e., 30LE) were captured with a
comparable efficiency as WT virions when using beads
coated with anti-HLA-DR antibodies. The virus producer
cell type (i.e., MDMs or CD4+ T lymphocytes) has no effect
on the process of HLA-DR incorporation process by WT or
matrix mutant viruses. It should be noted that similar
observations were made when testing progeny viruses
harvested from autologous MDMs and CD4+ T cells
inoculated with WT and Env/Nef+ viruses that were
pseudotyped with VSV-G (data not shown).
In the present work, we provide evidence that host HLA-
DR is found embedded within HIV-1 particles that either do
not bear or carry much lower levels of Env glycoproteins
compared to wild-type viruses. This observation parallels
what is seen with ICAM-1 since this cell surface adhesion
molecule is efficiently anchored on virions independently of
Env (Beause´jour and Tremblay, 2004a), but is in sharpcontrast with the study by Poon and colleagues which is
focused on HLA class II incorporation (Poon et al., 2000).
The explanation for this discrepancy is currently unknown,
but differences in experimental methodologies may account
for the different results. For example, although both studies
have studied the same viral strain (i.e., NL4-3), we used a
semi-quantitative immunocapture assay with a monoclonal
anti-HLA-DR antibody that was followed by detection of
Rapid Communication 289captured viruses by a sensitive p24 test, a technique that
detects as low as 31.25 pg/ml of p24 (Martin and Tremblay,
2004), whereas Poon and co-workers first immunoprecipi-
tated viruses through the use of a polyclonal anti-HLA class
II antibody before detection by immunoblotting for Gag
proteins that can detect a minimum of 1–2 ng of a specific
protein (Burnette, 1981).
In summary, the precise mechanism through which host-
encoded HLA-DR molecules are incorporated within bud-
ding HIV-1 particles is still mysterious and further studies
are needed to shed light on this issue. We are currently
defining whether the association of HLA-DR with the
cytoskeleton might contribute to the efficient incorporation
of this cell surface protein onto HIV-1 based on the idea that
oligomerization of HLA-DR molecules induces their asso-
ciation with the cytoskeleton and their recruitment into lipid
rafts (El Fakhry et al., 2004). Moreover, it has been recently
suggested that some cytoplasmic linker proteins might be
involved in acquisition of host ICAM-1 by nascent HIV-1
virions (Beause´jour and Tremblay, 2004b).Acknowledgments
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